Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial

Celgene Corporation CELG announced results from the phase II trial SLE 001 at the Annual European Congress of Rheumatology EULAR 2017 in Madrid The trial evaluated investigational candidate CC 220 The data showed greater improvement with CC 220 an oral immunomodulatory compound